Allele C-509T in the promoter region of the transforming growth factor β (TGFB1) associated with radiation-induced fibrosis risk of breast cancer in patients with early-stage breast cancer, according to a study published online July 19 JAMA in oncology.
Aaron J .. Grossberg, MD, of the University of MD Cancer Center of Texas in Houston, and colleagues examined the correlation between the allele variants of C-509T in the promoter region TGFB1 and fibrosis, breast cancer three years after radiation therapy in a cohort study were included in the open randomized clinical trial that compared hypofractionated whole breast irradiation (WBI) with conventionally fractionated WBI. Two hundred and eighty-seven women aged 40 years and older with pathologically confirmed stage from 0 to IIA breast cancer who underwent breast conservation surgery, they have been reported and were followed for at least three years.
TGFB1 genotype and three-year data on the toxicity caused by radiation therapy were available for 174 patients, of which 51 percent had at least one copy of the C-509T. Researchers have found that in 13.8% of patients with C-509T and 3.8 per cent of them had fibrosis chest level 2 or above without allelic variant. In the multiparameter assay only factors significantly associated with risk of breast fibrosis, were C-509T and postoperative cosmetic outcomes (odds ratios 4.47 and 7.09 respectively).
"Allele C-509T in TGFB1 is a key factor in breast cancer risk of fibrosis," the authors write. "Evaluation TGFB1 genotype may contribute a personalized approach to solutions with locoregional treatment of breast cancer."
Two authors disclosed financial ties to the pharmaceutical and medical devices.